Research programme: irritable bowel syndrome therapeutics - RaQualia

Drug Profile

Research programme: irritable bowel syndrome therapeutics - RaQualia

Alternative Names: RQ-00202730

Latest Information Update: 23 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer RaQualia Pharma
  • Class
  • Mechanism of Action Cannabinoid receptor CB2 agonists; Serotonin 2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Irritable bowel syndrome

Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 22 Feb 2016 Discontinued for Irritable bowel syndrome in Japan (unspecified route)
  • 31 Dec 2011 RaQualia's irritable bowel syndrome therapeutics programme is available for licensing in World as of 31 Dec 2011.
  • 14 Apr 2009 Early research in Irritable bowel syndrome in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top